Table 1.
Differentiation of RCC subtypes
| Marker | Clear cell RCC | Papillary RCC Type 1 | Papillary RCC Type 2 | Chromophobe RCC | Oncocytoma | Xp11.2 translocation RCC |
|---|---|---|---|---|---|---|
| VHL mutation | + (~90%) | - | - | - | - | - |
| cMET mutation | - | + | - | - | - | - |
| TP53 mutations | - | - | - | + | - | - |
| Other mutations | PBRM1 (~50%), BAP1 (~15%), SETD2 (~15%) | NRF2, CUL3 | FH | - | Mitochondrial complex I genes | translocations of Xp11.2 (TFE3) or 6p21 (TFEB) |
| CK8 | +/- | + | + | +/- | + | ND |
| CAIX | + | +/- | + | - | - | + |
| CAM 5.2 | + | + | + | + | + | - |
| CD10 | + | + | + | +/- | +/- | + |
| CD15 | + | + | + | - | + | ND |
| CK18 | + | + | + | + | + | ND |
| EMA | + | + | + | + | + | - |
| GST-alpha | + | - | - | - | - | ND |
| PAX2 | + | + | +/- | - | + | +/- |
| PAX8 | + | + | + | + | - | + |
| RCC Ma | + | + | +/- | - | - | + |
| VIM | + | + | + | - | - | + |
| AMACR | - | + | + | - | - | + |
| CD117 | - | - | - | + | + | ND |
| CK7 | - | +/- | -/+ | +/- | - | +/- |
| CK19 | - | - | - | - | - | +/- |
| CK20 | - | - | - | - | - | - |
| c-KIT | - | +/- | +/- | + | + | ND |
| CLDN7/8 | - | - | - | + | + | ND |
| E-cadherin | - | + | +/- | + | - | + |
| EpCAM | - | - | -/+ | + | +/- | ND |
| Ksp-cad | - | - | - | - | + | + |
| PVALB | - | - | - | + | +/- | ND |
| TFE3 | - | - | - | - | - | + |
| SMA | - | - | - | - | + | ND |
Legend: AMACR α-methylacyl coenzyme A racemase, CAIX carbonic anhydrase IX, CK7 cytokeratin 7, CLDN7/8 claudin 7/8, EMA epithelial membrane antigen, GST-alpha glutathione S-transferase alpha, EpCAM epithelial cell adhesion molecule, Ksp-cad kidney-specific cadherin, PVALB parvalbumin, RCC Ma renal cell carcinoma marker, SMA smooth muscle action, TFE3 Transcription factor E3 - transcription factor binding to IGHM enhancer 3, PAX2/8 paired box gene 2/8, VIM vimentin, ND no reported data